Healthcare - Biotechnology - NASDAQ - US
$ 0.8639
-3.72 %
$ 59.3 M
Market Cap
-0.53
P/E
CASH FLOW STATEMENT
-100 M
OPERATING CASH FLOW
71 M
INVESTING CASH FLOW
2.94 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Vor Biopharma Inc.
| Net Income | -118 M |
| Depreciation & Amortization | 3.49 M |
| Capital Expenditures | -1.07 M |
| Stock-Based Compensation | 13.4 M |
| Change in Working Capital | 650 K |
| Others | -2.13 M |
| Free Cash Flow | -101 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (117.9) | (92.1) | (68.9) | (43.3) | (10.8) | (4.2) |
| Depreciation & Amortization | 3.5 | 2.5 | 1.4 | 0.6 | 91 K | 20 K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 32 K | 0.3 |
| Stock Based Compensation | 13.4 | 10.7 | 4.3 | 1.3 | 0.2 | 0.1 |
| Other Operating Activities | 67 K | 6.4 | 3.2 | 0.8 | 0.6 | 1.0 |
| Change in Working Capital | 0.7 | (12.7) | (9.2) | 4.3 | 0.1 | 63 K |
| Cash From Operations | (100.3) | (85.1) | (69.1) | (36.3) | (9.9) | (2.7) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (1.1) | (8.5) | (3.9) | (4.2) | (0.7) | 0 |
| Other Items | 72.1 | (85.6) | (87.8) | 0 | 0 | 0 |
| Cash From Investing Activities | 71.0 | (94.1) | (91.7) | (4.2) | (0.7) | 0 |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | (1.2) | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 2.5 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.6) | 1.2 | 43.7 | 82.5 | 17.7 | 0 |
| Cash From Financing Activities | 2.9 | 117.1 | 232.9 | 82.5 | 17.7 | 2.5 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (26.3) | (62.1) | 72.1 | 42.1 | 7.1 | (0.2) |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (101.4) | (93.6) | (73.0) | (40.5) | (10.6) | (2.7) |